The purpose of this research study is to better understand, from the perspective of Black patients, whether telemedicine visits make prostate cancer decision making easier or harder. The COVID-19 pandemic made it more difficult for patients to see their doctors, but care could continue by having appointments via a computer or phone, which many prostate cancer doctors used. Whether in person or remote, successfully choosing a treatment for prostate cancer often uses shared decision making (SDM), the process where doctors and patients work together to make decisions that match what matters to patients, but it is unknown whether virtual appointments make discussions better or worse. Other studies have shown that Black patients may be less satisfied with their treatment choices than non-Black patients. Therefore, it is important that we understand how to improve the same quality of care for Black patients.

To evaluate whether early drug treatment extends overall survival compared with delayed drug treatment with high-risk (chronic lymphocytic leukemia [CLL] newly diagnosed asymptomatic CLL/SLL patients.

To find the safest and most tolerable dose of CAR.B7-H3 T cells to administer in patients with relapsed/refractory platinum-resistant epithelial ovarian cancer.

Immune checkpoint inhibitors (ICIs) are a type of cancer treatment that work by over-activating the immune system to find and kill cancer cells. This type of treatment can sometimes lead to side effects that look like autoimmune diseases (diseases where the immune system attacks the body). We want to collects samples and clinical data from cancer patients taking ICI therapy to understand why some patients get side effects and others don't.

Do you have mantle cell lymphoma or other non-Hodgkin lymphoma that has either come back or did not get better with your last treatment? If so, you may be able to take part in a study that will modify your own immune cells to see if it may treat your cancer.

Have you been diagnosed with primary central nervous system (CNS) lymphoma? If so you may be able to take part in a research study looking at whether using the study drugs lenalidomide, and nivolumab can be safely used in addition to the standard treatment of primary CNS lymphoma, and which dose is the most adequate when they are used together.

The purpose of this study is to test whether giving the study drug acalabrutinib is safe and could help control B-cell Non-Hodgkin CNS lymphoma that have not gone away, or have come back, after the first round of treatment.

Do you want to help us learn more about skin cancers with little effort on your part? We would like to collect data from your medical record and use tissues sitting in storage to help us better understand how skin cancers work and find treatments/cures. Contact us today to find out how you can be a part of ground-breaking research!

The purpose of this research study is to deliver 6 months of 1:1 health coaching to cancer patients being treated at UNC Cancer Hospital. This program hopes to improve patient's self-confidence and satisfaction with how they feel and what they are able to do day-to-day. This includes exercising, support for healthy eating, emotional and social needs. Health coaching means you will receive weekly phone calls and emails from a trained coach.

Will you be treated for Locally Advanced Head and Neck Squamous Cell Carcinoma? Have you been cancer free for at least two years after previous treatment? If so, you may eligible to participate in a clinical research trial aimed to measure the level of ctDNA in the blood before and after treatment.